dc.contributor.advisor | Islam, Farzana | |
dc.contributor.author | Karim, Azrin | |
dc.date.accessioned | 2024-10-22T06:34:58Z | |
dc.date.available | 2024-10-22T06:34:58Z | |
dc.date.copyright | ©2024 | |
dc.date.issued | 2024-01 | |
dc.identifier.other | ID 20146077 | |
dc.identifier.uri | http://hdl.handle.net/10361/24372 | |
dc.description | This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024. | en_US |
dc.description | Cataloged from PDF version of project report. | |
dc.description | Includes bibliographical references (pages 43-46). | |
dc.description.abstract | This review delves into the intricate landscape of Poly ADP-ribose polymerase (PARP)
inhibitors, specifically focusing on two notable contenders in cancer therapy – Talazoparib and
Olaparib. By targeting the DNA Damage Repair (DDR) signaling system crucial for cancer
growth, these inhibitors disrupt essential mechanisms like homologous recombination, base
excision repair, and mismatch repair.
Talazoparib, a PARP inhibitor, has demonstrated its potential as a breakthrough in metastatic
breast cancer with BRCA1/2 mutations, surpassing traditional chemotherapy in efficacy.
Through PARP trapping and catalytic inhibition, Talazoparib disrupts repair processes, earning
approval for BRCA-mutated breast cancer and homologous recombination repair (HRR)
gene-mutated metastatic castration-resistant prostate cancer.Similarly, Olaparib, another PARP
inhibitor, is approved for treating pancreatic, ovarian, breast, and prostate cancers. Its impact on
synthetic lethality in cancer cells with BRCA mutations is evident, blocking PARP-mediated
repair of single-strand breaks. Clinical trials affirm Olaparib's manageable safety profile and
efficacy in treating HER2-negative metastatic breast cancer, prostate cancer, and ovarian cancer.
The study concludes that Olaparib and Talazoparib stand as effective therapeutic options across
various cancer types and genetic abnormalities. It aims to enlighten medical professionals about
the potential of precision medicine in advancing cancer therapy, emphasizing the need for
personalized approaches in clinical practice. | en_US |
dc.description.statementofresponsibility | Azrin Karim | |
dc.format.extent | 47 pages | |
dc.language.iso | en | en_US |
dc.publisher | Brac University | en_US |
dc.rights | Brac University project reports are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. | |
dc.subject | PARP inhibitors | en_US |
dc.subject | Olaparib | en_US |
dc.subject | Talazoparib | en_US |
dc.subject | DNA damage repair | en_US |
dc.subject | DDR signaling pathway | en_US |
dc.subject | Homologous recombination repair | en_US |
dc.subject | Prostate cancer | en_US |
dc.subject | Ovarian cancer | en_US |
dc.subject | Metastatic breast cancer | en_US |
dc.subject | BRCA mutations | en_US |
dc.subject.lcsh | Cancer--Treatment--Genetic aspects. | |
dc.subject.lcsh | DNA repair. | |
dc.subject.lcsh | NAD-ADP-ribosyltransferase--Inhibitors--Therapeutic use. | |
dc.subject.lcsh | Antineoplastic agents. | |
dc.title | A review on newly approved PARP inhibitors: Talazoparib and Olaparib | en_US |
dc.type | Project report | en_US |
dc.contributor.department | School of Pharmacy, Brac University | |
dc.description.degree | B. Pharmacy | |